Soquelitinib Medicine 04 December 2025 Extended indication Soquelitinib monotherapy for third line or later treatment of relapsed or refractory peripheral T-cell lymphoma in adults and elderly. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Soquelitinib Domain Hematology Reason of inclusion New medicine (specialité) Main indication Aggressive non-Hodgkin’s lymphoma Extended indication Soquelitinib monotherapy for third line or later treatment of relapsed or refractory peripheral T-cell lymphoma in adults and elderly. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Corvus Portfolio holder Corvus Mechanism of action Route of administration Oral Therapeutical formulation Capsule Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP No Submission date May 2026 Expected Registration June 2027 Orphan drug Yes Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References NCT06561048 Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Zhang & Dalal. Value in Health. 2019 (1). Additional remarks Perifeer T-cellymfoom is een zeldzame aandoening. De incidentie voor perifeer T-cellymfoom wordt geschat op 0,62 per 100.000 (1), wat neerkomt op zo'n 110 diagnoses in Nederland per jaar. Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks